Questionnaire administration: Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
Study summary
The aim of this prospective, longitudinal Swedish multi-center study is to assess the quality of life, treatment-related morbidity, unmet needs and satisfaction with care after treatment for vulvar cancer, evaluated by a validated questionnaire.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Primary diagnosis of vulvar cancer, all stages, all planned treatments
* Informed consent
Exclusion Criteria:
* Disability to understand and complete the questionnaire due to language difficulties, severe psychiatric illness or dementia
Primary outcome measure(s)
Global quality of life — 1 year after end of treatment Measured by the European Organisation of Research and Treatment of Cancer (EORTC)-QLQ-C30-questionnaire.
Measurement on a scale between 0-and 100. Higher values represent better quality of life. A change of at least 5-8 points is regarded as clinically significant.
Vulvar-cancer-specific quality of life — 1 year after end of treatment Measured by the EORTC-QLQ-VU34-questionnaire. Higher values represent higher quality of life.
Trial sites (4)
Facility
City
Region
Status
Karolinska University Hospital
Stockholm
Stockholm County
Sahlgrenska University Hospital
Gothenburg
Sweden
Linkopings University Hospital
Linköping
Sweden
Skanes University Hospital Lund
Lund
Sweden
More Karolinska University Hospital trials in Sweden
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
